Overexpression of HER2 modulates bcl-2, Bcl-X(L) and tamoxifen induced apoptosis in human MCP-7 breast cancer cells

Clinical Cancer Research

Volumn 2, Issue 7, 1996, Pages 1215-1219

  Kumar, Rakesh ^a,c   Mandal, Mahitosh ^a   Lipton, Allan ^a   Harvey, Harold ^a   Thompson, Craig B ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; DOSE RESPONSE; FEMALE; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0029888125     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jordan, V. C. A current view of tamoxifen resistance in breast cancer. Br. J. Pharmacol., 110: 507-517. 1993.
2. Stern, D. F., Heffernan, P. A., and Weinberg, R. A. P185, a product of the neu proto-oncogene, is a receptor like protein associated with tyrosine kinase activity. Mol. Cell. Biol., 6: 1729-1740, 1986.
3. Slamon, D. J., de Kernion, J. B., Verma, I. M., and Cline, M. J. Expression of cellular oncogenes in malignancies. Science (Washington DC), 244: 256-262, 1994.
4. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, M., and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24: 85-95, 1995.
5. Wright, C., Nicholson. S., Angus, B., Sainsbury, J. R. C., Farndon, J., Cairns, J., Harris, A. L., and Horne, C. H. W. Relationship between c-erb-B2 protein product expression and response to endocrine therapy in advanced breast cancer Br. J. Cancer, 65: 118-121, 1992.
6. Leitzel, K., Teramoto. Y., Konrad. K., Chinchilli, V. M., Volas, G., and Lipton, A. Elevated serum c-erb-B2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol., 13: 1129-1135, 1995.
7. Korsmeyer, S. J. Bcl-2 initiates a new category of oncogenes: regulator of cell death. Blood, 80: 879-886, 1992.
8. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 267: 1456-1462, 1995.
9. Boise, L. H., Gonzalez-Garcia, M., Postema, C E., Ding, L., Lindsten, T., Turka, L. A , Mao, X., Nunez, G., and Thompson, C. B Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74: 597-608, 1993.
10. Sedlak, T. W., Olltvai, Z. N, Yang, E., Wang, K., Boise, L. H., Thompson, C. B., and Korsmeyer, S. J. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc. Natl. Acad. Sci. USA, 92: 7834-7838, 1995
11. Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., and Borscchi, P. The Bcl-2 protein, a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer in patients. J. Natl. Cancer Inst , 86: 499-504, 1994.
12. Leek, R. D., Kakalamanis, L., Pezzella, F., Gatter, K. C., and Harris, A. L. Bcl-2 in normal human breast and carcinoma: association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. Br. J. Cancer, 69: 135-139, 1994.
13. Gee, J. M. W., Robertson, J. F. R., Ellis, I. O. Willsher, P., McClelland, R. A , Hoyle, H B., Kyme, S. R., Finlay, P., Blamey, R W., and Nicholson. R. I. Immunochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer, 59: 619-628, 1994.
14. s sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res., 55: 2507-2510, 1995.
15. Mandal, M., and Kumar, R. Bcl-2 expression regulates sodium butyrate-mduced apoptosis in human MCF-7 breast cancer cells. Cell Growth & Differ , 7: 311-318, 1996.
16. Wang, T. Y., and Phang, J. M. Effect of estrogen on apoptotic pathways in human breast cancer cell MCF-7. Cancer Res., 55: 2487-2489, 1995.
17. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev., 11: 121-139, 1992.
18. Kumar, R., Korutla, L., and Zhang, K. Cell cycle-dependent modulation of α interferon inducible genes expression and activation of signaling components in Daudi cells. J. Biol. Chem , 269: 25437-25441, 1994.
19. Kumar, R., Shepard, H. M., and Mendelsohn, J. Regulation of phosphorylation of c-erbB2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol. Cell. Biol., 11: 979-986, 1991.
20. Ma, A., Pena, J. C., Chang, B , Margosian, E., Davidson, L., Alt, F. W., and Thompson, C B. Bcl-x regulates the survival of double-positive thymocytes. Proc. Natl. Acad. Sci. USA, 92: 4763-4767, 1995.
21. Krajewski, S., Blomquist, C., Franssila, K., Krajewska, M., Wasenius, V-M., Niskanen, E., Nordling, S., and Reed, J C. Reduced expression of proapoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res., 55: 4471-4478, 1995.
22. Teixeira C, Reed, J. C., and Pratt, M. A. C. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res., 55: 3902-3907, 1995.